Similar articles for PMID: 32009094

Year	Number of Results
2016	2
2017	6
2018	35
2019	45
2020	13
2021	4
2022	2
2024	0

1

Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report.

Hijikata Y, Matsubara Y, Ota Y, Lim LA, Tani K, Hirata Y, Yotsuyanagi H. Hijikata Y, et al. Intern Med. 2020 Apr 15;59(8):1105-1109. doi: 10.2169/internalmedicine.3901-19. Epub 2020 Feb 1. Intern Med. 2020. PMID: 32009094 Free PMC article.

2

Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.

Yoshino K, Nakayama T, Ito A, Sato E, Kitano S. Yoshino K, et al. BMC Cancer. 2019 Oct 29;19(1):1019. doi: 10.1186/s12885-019-6138-7. BMC Cancer. 2019. PMID: 31664934 Free PMC article.

3

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.

Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N. Masuda K, et al. BMC Cancer. 2019 Oct 21;19(1):974. doi: 10.1186/s12885-019-6150-y. BMC Cancer. 2019. PMID: 31638948 Free PMC article.

4

Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.

Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, Suzuki K, Shimizu H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y. Toi Y, et al. JAMA Oncol. 2019 Mar 1;5(3):376-383. doi: 10.1001/jamaoncol.2018.5860. JAMA Oncol. 2019. PMID: 30589930 Free PMC article.

5

An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.

Miyahara K, Noda T, Ito Y, Hidaka H, Fujimoto S, Takedomi H, Akutagawa T, Sakata Y, Shimamura T, Tominaga N, Yamaguchi D, Fujimoto K. Miyahara K, et al. Digestion. 2020;101(1):60-65. doi: 10.1159/000504647. Epub 2019 Dec 4. Digestion. 2020. PMID: 31801131

6

Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.

Oyanagi J, Koh Y, Sato K, Mori K, Teraoka S, Akamatsu H, Kanai K, Hayata A, Tokudome N, Akamatsu K, Nakanishi M, Ueda H, Yamamoto N. Oyanagi J, et al. Lung Cancer. 2019 Jun;132:107-113. doi: 10.1016/j.lungcan.2019.03.020. Epub 2019 Mar 22. Lung Cancer. 2019. PMID: 31097082

7

Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor.

Alessandrino F, Sahu S, Nishino M, Adeni AE, Tirumani SH, Shinagare AB, Awad MM. Alessandrino F, et al. Abdom Radiol (NY). 2019 May;44(5):1917-1927. doi: 10.1007/s00261-019-01935-2. Abdom Radiol (NY). 2019. PMID: 30790009

8

A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine.

Kikuchi H, Sakuraba H, Akemoto Y, Murai Y, Fukutoku Y, Asari T, Tatsuta T, Hasui K, Hiraga H, Sawaya M, Chinda D, Mikami T, Tanaka M, Fukuda S. Kikuchi H, et al. Immunol Med. 2019 Mar;42(1):39-44. doi: 10.1080/25785826.2019.1580477. Epub 2019 Mar 27. Immunol Med. 2019. PMID: 30917094

9

Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.

Toi Y, Sugawara S, Kawashima Y, Aiba T, Kawana S, Saito R, Tsurumi K, Suzuki K, Shimizu H, Sugisaka J, Ono H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y. Toi Y, et al. Oncologist. 2018 Nov;23(11):1358-1365. doi: 10.1634/theoncologist.2017-0384. Epub 2018 Jun 22. Oncologist. 2018. PMID: 29934411 Free PMC article.

10

Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.

Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, Brambilla M, Baglivo S, Grossi F, Chiari R. Ricciuti B, et al. J Cancer Res Clin Oncol. 2019 Feb;145(2):479-485. doi: 10.1007/s00432-018-2805-3. Epub 2018 Dec 1. J Cancer Res Clin Oncol. 2019. PMID: 30506406

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

94 results

Results by year